CN101489556A - 糖皮质激素受体调节剂及使用方法 - Google Patents

糖皮质激素受体调节剂及使用方法 Download PDF

Info

Publication number
CN101489556A
CN101489556A CNA2007800258079A CN200780025807A CN101489556A CN 101489556 A CN101489556 A CN 101489556A CN A2007800258079 A CNA2007800258079 A CN A2007800258079A CN 200780025807 A CN200780025807 A CN 200780025807A CN 101489556 A CN101489556 A CN 101489556A
Authority
CN
China
Prior art keywords
compound
added
chloro
oxa
dibenzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800258079A
Other languages
English (en)
Chinese (zh)
Inventor
M·W·卡森
M·J·科格伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN101489556A publication Critical patent/CN101489556A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA2007800258079A 2006-07-14 2007-07-12 糖皮质激素受体调节剂及使用方法 Pending CN101489556A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83116606P 2006-07-14 2006-07-14
US60/831,166 2006-07-14

Publications (1)

Publication Number Publication Date
CN101489556A true CN101489556A (zh) 2009-07-22

Family

ID=38924180

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800258079A Pending CN101489556A (zh) 2006-07-14 2007-07-12 糖皮质激素受体调节剂及使用方法

Country Status (14)

Country Link
US (1) US8101760B2 (enExample)
EP (1) EP2043646B1 (enExample)
JP (1) JP5189091B2 (enExample)
KR (1) KR20090020694A (enExample)
CN (1) CN101489556A (enExample)
AU (1) AU2007272504B2 (enExample)
BR (1) BRPI0714811A2 (enExample)
CA (1) CA2655202A1 (enExample)
CL (1) CL2007003501A1 (enExample)
EA (1) EA014695B1 (enExample)
ES (1) ES2384057T3 (enExample)
MX (1) MX2009000583A (enExample)
TW (1) TW200902537A (enExample)
WO (1) WO2008008882A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102746219A (zh) * 2012-07-02 2012-10-24 盛世泰科生物医药技术(苏州)有限公司 一种2-羧基-3-溴吡啶盐酸盐的合成方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200829578A (en) 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
ATE522537T1 (de) * 2008-01-11 2011-09-15 Lilly Co Eli (e)-n-ä3-ä1-(8-fluor-11h-10-oxa-1-aza-dibenzo-ä , dü-cyclohepten-5-yliden)-propylü-phenylü- methylsulfon-amid als glucocorticoid- rezeptormodulator zur behandlung rheumatoider arthritis
US8211930B2 (en) 2008-05-20 2012-07-03 Astrazeneca Ab Phenyl and benzodioxinyl substituted indazoles derivatives
US20110112299A1 (en) * 2008-07-03 2011-05-12 Kyowa Hakko Kirin Co., Ltd. Tetracyclic compound
WO2011081173A1 (ja) * 2009-12-29 2011-07-07 協和発酵キリン株式会社 四環系化合物
AR117951A1 (es) * 2018-07-20 2021-09-08 Gruenenthal Gmbh Derivados de triazolquinoxalina adicionalmente sustituidos

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2603713B1 (fr) 1986-09-10 1992-07-24 Canon Kk Derive nouveau de 5h-dibenzo(a,d)cycloheptane-(ene)ylidene, son procede de production et support electrophotographique photosensible le contenant
JPH01161245A (ja) 1987-12-18 1989-06-23 Canon Inc 電子写真感光体
CA1338625C (en) 1988-06-09 1996-10-01 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
US5093210A (en) 1989-06-30 1992-03-03 Ricoh Company, Ltd. Electroluminescent device
US5378701A (en) 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
ZA9811898B (en) 1997-12-29 2000-06-28 Ortho Mcneil Pharm Inc Anti-Inflammatory Compounds.
EP1154997A4 (en) 1999-01-26 2002-11-04 Dana Farber Cancer Inst Inc PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE
TW200400816A (en) * 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
TWI291467B (en) * 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102746219A (zh) * 2012-07-02 2012-10-24 盛世泰科生物医药技术(苏州)有限公司 一种2-羧基-3-溴吡啶盐酸盐的合成方法

Also Published As

Publication number Publication date
CA2655202A1 (en) 2008-01-17
EP2043646A2 (en) 2009-04-08
US8101760B2 (en) 2012-01-24
MX2009000583A (es) 2009-01-27
EP2043646B1 (en) 2012-05-16
EA014695B1 (ru) 2010-12-30
TW200902537A (en) 2009-01-16
AU2007272504A1 (en) 2008-01-17
AU2007272504B2 (en) 2012-06-28
EA200970127A1 (ru) 2009-04-28
US20100069425A1 (en) 2010-03-18
KR20090020694A (ko) 2009-02-26
JP5189091B2 (ja) 2013-04-24
CL2007003501A1 (es) 2008-07-04
WO2008008882A3 (en) 2008-05-02
WO2008008882A2 (en) 2008-01-17
ES2384057T3 (es) 2012-06-28
JP2009543804A (ja) 2009-12-10
BRPI0714811A2 (pt) 2014-02-18

Similar Documents

Publication Publication Date Title
CN101489556A (zh) 糖皮质激素受体调节剂及使用方法
JP2020128385A (ja) エストロゲン受容体調節剤としての6,7−ジヒドロ−5h−ベンゾ[7]アヌレン誘導体
CA2648196A1 (en) Use of biarylcarboxamides in the treatment of hedgehog pathway-related disorders
CN115605475B (zh) 一种免疫抑制剂、其制备方法和应用
JPWO2008001859A1 (ja) オピオイドδ受容体アゴニスト
WO2015060373A1 (ja) キナゾリノンおよびイソキノリノン誘導体
CN111943889B (zh) 一种双芳香基胺类化合物及其制备方法和应用
Kaitoh et al. Design, synthesis and biological evaluation of novel nonsteroidal progesterone receptor antagonists based on phenylamino-1, 3, 5-triazine scaffold
AU2014354085B2 (en) Novel 3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purposes
Singh et al. Synthesis and structure guided evaluation of estrogen agonist and antagonist activities of some new tetrazolyl indole derivatives
CN101910179B (zh) 糖皮质激素受体调节剂及使用方法
CN114699412A (zh) 磺酰胺类化合物及其在制备治疗自身免疫性疾病药物中的应用
CN110023300B (zh) 作为tnf活性的调节剂的取代的苯并咪唑衍生物
US20160052936A1 (en) Spiroindoline derivatives for use as gonadotropin-releasing hormone receptor antagonists
TW202446373A (zh) 二氧代哌啶化合物或其可藥用鹽的無定形物、結晶、製備方法和用途
CN119768396A (zh) 新颖的取代的苯并噻吩-6-羧酸衍生物、其制备方法及其治疗用途
CN112218852A (zh) 氧化的双(3-吲哚基)甲烷及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20090722